To determine whether GQ1b improves cognitive impairments in transgenic mouse models of AD, we used 3xTg-AD mice at advanced stages of the disease (18–22 months), that had already developed Aβ, tau pathology and showed decreased BDNF expression in the hippocampus (Supplementary Fig. 2A–E). Here, MAPT is linked to Alzheimer disease.